{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["36(9)"],"submitter":["Mesa R"],"pubmed_abstract":["Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom improvements but do not address anemia, a negative prognostic factor. Momelotinib, an inhibitor of ACVR1/ALK2, JAK1 and JAK2, demonstrated activity against anemia, symptoms, and splenomegaly in the phase 3 SIMPLIFY trials. Here, we report mature overall survival (OS) and leukemia-free survival (LFS) from both studies, and retrospective analyses of baseline characteristics and efficacy endpoints for OS associations. Survival distributions were similar between JAKi-naïve patients randomized to momelotinib, or ruxolitinib then momelotinib, in SIMPLIFY-1 (OS HR = 1.02 [0.73, 1.43]; LFS HR = 1.08 [0.78, 1.50]). Two-year OS and LFS were 81.6% and 80.7% with momelotinib and 80.6% and 79.3% with ruxolitinib then m"],"journal":["Leukemia"],"pagination":["2261-2268"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9417985"],"repository":["biostudies-literature"],"pubmed_title":["Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis."],"pmcid":["PMC9417985"],"pubmed_authors":["Lech-Maranda E","Oh ST","Kiladjian JJ","Platzbecker U","Gupta V","Strouse B","Huang M","Cervantes F","Catalano J","Klencke B","Mesa R","Harrison C","Vannucchi AM","Gerds AT","Verstovsek S","Devos T","McLornan D","Hus M"],"additional_accession":[]},"is_claimable":false,"name":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.","description":"Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom improvements but do not address anemia, a negative prognostic factor. Momelotinib, an inhibitor of ACVR1/ALK2, JAK1 and JAK2, demonstrated activity against anemia, symptoms, and splenomegaly in the phase 3 SIMPLIFY trials. Here, we report mature overall survival (OS) and leukemia-free survival (LFS) from both studies, and retrospective analyses of baseline characteristics and efficacy endpoints for OS associations. Survival distributions were similar between JAKi-naïve patients randomized to momelotinib, or ruxolitinib then momelotinib, in SIMPLIFY-1 (OS HR = 1.02 [0.73, 1.43]; LFS HR = 1.08 [0.78, 1.50]). Two-year OS and LFS were 81.6% and 80.7% with momelotinib and 80.6% and 79.3% with ruxolitinib then m","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-18T22:54:41.214Z","creation":"2025-04-07T10:36:04.36Z"},"accession":"S-EPMC9417985","cross_references":{"pubmed":["35869266"],"doi":["10.1038/s41375-022-01637-7"]}}